secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2026-07-13T10:30:23+00:00
Accession:  0001193125-26-301414
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus raises $85M upfront (up to $340M) to fund registrational Phase 3 ROBBIN trial of BOT+BAL in MSS colon cancer
--------------------------------------------------------------------------------

- Private placement of $85M upfront gross proceeds, plus up to $255M from warrant exercise; total up to $340M.
- Proceeds to fund ROBBIN Phase 3 trial in neoadjuvant MSS colon cancer; expected runway through year-end 2031 if warrants exercised.
- ROBBIN trial to enroll 850 patients, primary endpoint EFS; first patient dosed Q1 2027, interim pathologic response data H2 2027.
- Discontinuing financial support for BATTMAN Phase 3 in late-line metastatic MSS CRC.
- Phase 2 data: pathologic response ~60-70%, MPR ~35-40%, pCR ~30%; all patients disease-free at median 9-18 months follow-up.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000119312526301414/0001193125-26-301414-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000119312526301414/d111026d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-301414

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer